PFS Partners’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.92K Sell
321
-5
-2% -$38 ﹤0.01% 521
2025
Q4
$2.33K Buy
326
+1
+0.3% +$8 ﹤0.01% 507
2025
Q3
$3.47K Buy
325
+1
+0.3% +$10 ﹤0.01% 458
2025
Q2
$3.14K Buy
324
+1
+0.3% +$10 ﹤0.01% 435
2025
Q1
$4.82K Buy
323
+5
+2% +$77 ﹤0.01% 348
2024
Q4
$4.74K Buy
318
+1
+0.3% +$16 ﹤0.01% 355
2024
Q3
$6.06K Buy
317
+4
+1% +$83 ﹤0.01% 329
2024
Q2
$6.47K Buy
313
+5
+2% +$99 ﹤0.01% 312
2024
Q1
$5.8K Buy
308
+3
+1% +$51 ﹤0.01% 330
2023
Q4
$4.4K Buy
305
+7
+2% +$95 ﹤0.01% 358
2023
Q3
$5.17K Buy
298
+4
+1% +$83 ﹤0.01% 327
2023
Q2
$6.11K Buy
294
+4
+1% +$87 0.01% 314
2023
Q1
$6.82K Buy
290
+4
+1% +$107 0.01% 250
2022
Q4
$8K Buy
286
+14
+5% +$358 0.01% 225
2022
Q3
$6.38K Buy
272
+2
+0.7% +$60 0.01% 235
2022
Q2
$9.12K Buy
270
+2
+0.7% +$70 0.01% 208
2022
Q1
$9.36K Sell
268
-3
-1% -$103 0.01% 219
2021
Q4
$8.24K Buy
+271
New +$8.83K 0.01% 222

Other funds holding OGN

PFS Partners's OGN Position: Q1 2026 in Review

PFS Partners reduced its Organon & Co (OGN) stake by 1.5% in Q1 2026, selling an estimated $38 and leaving 321 shares worth $1.92K. The position accounts for ﹤0.01% of the portfolio, ranked #521.

PFS Partners first reported a position in OGN in Q4 2021 and has held it in 18 quarters since. The position peaked at $9.36K in Q1 2022. 603 funds tracked by Wall St. Rank hold OGN as of Q1 2026.

  • PFS Partners held 321 shares of Organon & Co worth $1.92K as of Q1 2026.
  • PFS Partners sold 5 Organon & Co shares in Q1 2026, an estimated $38.
  • Organon & Co made up ﹤0.01% of PFS Partners's portfolio in Q1 2026, its #521 holding.
  • PFS Partners first reported a position in Organon & Co in Q4 2021 and has held it in 18 quarters since.
  • PFS Partners's Organon & Co position peaked at $9.36K in Q1 2022.
  • 603 funds tracked by Wall St. Rank held Organon & Co as of Q1 2026.

Based on PFS Partners's 13F filing for Q1 2026, filed 9 Apr 2026.